Goldman Sachs
ANTX icon

Goldman Sachs’s AN2 Therapeutics ANTX Stock Holding History

Goldman Sachs’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426K Buy
+87,933
New +$378K ﹤0.01% 5798
2024
Q3 		– Sell
-224,185
Closed -$482K – 5801
2024
Q2 		$482K Buy
224,185
+195,815
+690% +$466K ﹤0.01% 4854
2024
Q1 		$92.2K Buy
28,370
+14,324
+102% +$156K ﹤0.01% 5256
2023
Q4 		$288K Buy
+14,046
New +$235K ﹤0.01% 5026
2023
Q3 		– Sell
-39,107
Closed -$332K – 5523
2023
Q2 		$332K Buy
+39,107
New +$281K ﹤0.01% 4963
2022
Q2 		– Sell
-19,497
Closed -$294K – 6438
2022
Q1 		$294K Buy
+19,497
New +$296K ﹤0.01% 5669

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs's ANTX Position: Q2 2026 in Review

Goldman Sachs opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 87,933 shares worth $426K. The stake represents ﹤0.01% of the portfolio and ranks #5798 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in ANTX as recently as Q2 2024.

Goldman Sachs first reported a position in ANTX in Q1 2022 and has held it in 6 quarters since. The position peaked at $482K in Q2 2024. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Goldman Sachs held 87,933 shares of AN2 Therapeutics worth $426K as of Q2 2026.
  • AN2 Therapeutics was a new Goldman Sachs position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5798 holding.
  • Goldman Sachs first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 6 quarters since.
  • Goldman Sachs's AN2 Therapeutics position peaked at $482K in Q2 2024.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.